{
    "text": "Biomarkers, such as PD-L1 and the tumor mutation burden (TMB), enable better selection of patients who should benefit the most from first-line ICI use in NSCLC.", 
    "denotations": [
        {
            "id": "T1", 
            "obj": "gene", 
            "span": {
                "begin": 20, 
                "end": 25
            }
        }, 
        {
            "id": "T2", 
            "obj": "disease", 
            "span": {
                "begin": 154, 
                "end": 159
            }
        }
    ], 
    "relations": [
        {
            "id": "R1", 
            "pred": "therapeutic", 
            "subj": "T2", 
            "obj": "T1"
        }
    ]
}